Dupilumab use in atopic dermatitis and beyond in skin diseases

被引：11
作者：
Fourzali, Kayla [1 ,2 ]
Golpanian, Rachel Shireen [1 ,2 ]
Yosipovitch, Gil [1 ,2 ]
机构：
[1] Univ Miami, Miller Sch Med, Dr Phillip Frost Dept Dermatol & Cutaneous Surg, 1600 NW 10th Ave,RMSB 2023, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Miami Itch Ctr, 1600 NW 10th Ave,RMSB 2023, Miami, FL 33136 USA
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 17期
关键词：
atopic dermatitis; clinical trials; cytokines; dupilumab; monoclonal antibody; pruritus; QUALITY-OF-LIFE; ADULT PATIENTS; UNITED-STATES; MODERATE; PLACEBO; IMPROVES; METAANALYSIS; ADOLESCENTS; MANAGEMENT; EFFICACY;
D O I：
10.2217/imt-2020-0175
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Atopic dermatitis (AD) is a chronic inflammatory condition that affects 5-10% of adults and 9-18% of children and its pathology is rooted in the Th-2-mediated immune response. Dupilumab is a fully human IgG4 monoclonal antibody that targets the IL-4 receptor alpha subunit that is endogenously bound by the Th-2 cytokines IL-4 and IL-13. Successful clinical trials of dupilumab showing marked improvements in clinical signs of AD, patient reported symptoms and quality of life measures led to its approval for clinical use for moderate-to-severe AD in 2017. This review details the current body of evidence on the drug's mechanism of action, pharmacology, clinical efficacy and safety as well as post market and real world use.
引用
收藏
页码：1221 / 1235
页数：15
相关论文
共 98 条
[1]   Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series [J].
Abdat, Rana ;
Waldman, Reid A. ;
de Bedout, Valeria ;
Czernik, Annette ;
Mcleod, Michael ;
King, Brett ;
Gordon, Samantha ;
Ahmed, Razzaque ;
Nichols, Anna ;
Rothe, Marti ;
Rosmarin, David .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) :46-52
[2]   Conjunctivitis in dupilumab clinical trials [J].
Akinlade, B. ;
Guttman-Yassky, E. ;
de Bruin-Weller, M. ;
Simpson, E. L. ;
Blauvelt, A. ;
Cork, M. J. ;
Prens, E. ;
Asbell, P. ;
Akpek, E. ;
Corren, J. ;
Bachert, C. ;
Hirano, I. ;
Weyne, J. ;
Korotzer, A. ;
Chen, Z. ;
Hultsch, T. ;
Zhu, X. ;
Davis, J. D. ;
Mannent, L. ;
Hamilton, J. D. ;
Teper, A. ;
Staudinger, H. ;
Rizova, E. ;
Pirozzi, G. ;
Graham, N. M. H. ;
Shumel, B. ;
Ardeleanu, M. ;
Wollenberg, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (03) :459-473
[3]   Erythema, pruritus, and diffuse peeling of skin during dupilumab therapy for atopic dermatitis in three adults [J].
Al Hammadi, Anwar ;
Parmar, Nisha V. .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2019, 58 (01) :E14-E15
[4]   Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review [J].
Almustafa, Zaid Z. ;
Weller, Karsten ;
Autenrieth, Juliane ;
Maurer, Marcus ;
Metz, Martin .
ACTA DERMATO-VENEREOLOGICA, 2019, 99 (10) :905-906
[5]  
[Anonymous], 2020, DUPIXENT DUPILUMAB I
[6]   Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry [J].
Ariens, Lieneke F. M. ;
van der Schaft, Jorien ;
Bakker, Daphne S. ;
Balak, Deepak ;
Romeijn, Margreet L. E. ;
Kouwenhoven, Tessa ;
Kamsteeg, Marijke ;
Giovannone, Barbara ;
Drylewicz, Julia ;
van Amerongen, Cynthia Catalina Aurora ;
Delemarre, Evelien M. ;
Knol, Edward F. ;
van Wijk, Femke ;
Nierkens, Stefan ;
Thijs, Judith L. ;
Schuttelaar, Marie L. A. ;
de Bruin-Weller, Marjolein S. .
ALLERGY, 2020, 75 (01) :116-126
[7]  
Armstrong AW, 2020, SOC INV DERM VIRT C
[8]   Epidemiology of atopic dermatitis in adults: Results from an international survey [J].
Barbarot, S. ;
Auziere, S. ;
Gadkari, A. ;
Girolomoni, G. ;
Puig, L. ;
Simpson, E. L. ;
Margolis, D. J. ;
de Bruin-Weller, M. ;
Eckert, L. .
ALLERGY, 2018, 73 (06) :1284-1293
[9]   Dupilumab-Associated Mucin Deficiency (DAMD) [J].
Barnett, Brad P. ;
Afshari, Natalie A. .
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2020, 9 (03)
[10]  
Barrett J, 2020, FDA APPROVES DUPILUM
12345678910